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AI = aromatase inhibitor; ER = oestrogen receptor; NSABP = National Surgical Adjuvant Breast and Bowel Project; RT-PCR = reverse transcription
polymerase chain reaction.
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During the 1990s, mortality from breast cancer finally
began to decline. This has been the result of a series of
factors, such as widespread screening and education (with
consequent early detection), new diagnostic techniques
and crucial therapeutic developments, particularly in the
area of new drugs. Notwithstanding these important
advances, metastatic breast cancer remains a virtually
incurable disease. The results of clinical trials and meta-
analyses have led to recommendations that some form of
adjuvant systemic therapy be administered to the great
majority of patients with breast cancer. The decision
regarding which specific therapy is given is based on
tumour and patient characteristics, but it is mainly empirical
because it extrapolates to the individual conclusions drawn
by studies conducted at the population level, leading to
inefficient treatment of many in order to benefit a few.
Accurate risk assessment and the ability to predict both
sensitivity and tolerability to treatments in each individual
patient have therefore became major goals and challenges
for the oncology community. The advent of microarray
technology and its potential clinical applications is an
important step toward tailored treatment.
The recently published study from the National Surgical
Adjuvant Breast and Bowel Project (NSABP) group lead by
Paik [1], in collaboration with Genomic Health Inc.,
represents a landmark trial in this field. Using quantitative
RT-PCR, these researchers developed a recurrence score
based on 21 genes that appears to predict accurately the
likelihood of distant recurrence in tamoxifen-treated patients
with node-negative, oestrogen receptor (ER)-positive breast
cancer. Initially, this predictor was designed to be a general
prognostic tool, developed in a mixed population of patients
receiving chemotherapy and tamoxifen. Following a
literature search of the most important microarray
experiments relating to breast cancer prognosis, 250
candidate genes were selected. Of these, 21 genes were
chosen and the recurrence score developed by analyzing
the results of these genes in three independent preliminary
studies involving 447 patients [2–4]. The selection of the
final 16 cancer-related genes was based primarily on the
strength of their performance in all three studies and the
consistency of primer or probe performance in the assay.
Cutoff points were chosen based on the results of NSABP
trial B-20, and allowed for the classification of patients into
three risk categories: low risk (recurrence score <18),
intermediate risk (recurrence score ≥18 and <31), and high
risk (recurrence score ≥31).
The report published in the New England Journal of
Medicine [1] describes the retrospective validation of this
multigene predictor in 675 archival samples from node-
negative, ER-positive breast cancer patients, treated with
adjuvant tamoxifen in the NSABP B-14 trial. Fifty-one per
cent of patients were classified as low risk, with a rate of
distant recurrence at 10 years of 6.8%, and 27% patients
were classified as high risk, with a rate of distant
recurrence at 10 years of 30.5%; this difference was
statistically significant (P < 0.001). The recurrence score
was also significantly correlated with the relapse-free
interval and overall survival (P < 0.001 for both). Notably,
this predictive power was independent of age and tumour
size (P < 0.001). The recurrence score also provided
significant information beyond tumour grade, despite the
low levels of concordance in assessment of grade
between the three pathologists in the study (43% overall).
There are additional important messages with potential
clinical implications. First, not all patients with small
(<1 cm) tumours were at low risk, because the recurrence
score classified 40% of these patients as intermediate or
high risk, with a 15–20% risk of distant recurrence at
10 years. Second, the subgroup of patients with
moderately differentiated tumours (the most common
grade) could be delineated into low-risk and high-risk
groups using the recurrence score.
As in all retrospective studies, bias in patient selection are
inevitable, and some relatively odd characteristics of the
patient population were the low rate of HER2 positivity
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(8.2%) and the absence of correlation between the levels
of ER or progesterone receptor proteins and the risk of
recurrence.
Because recurrence in the ipsilateral breast, local
recurrence, and regional recurrence were not considered
events or censoring events, this score should not be used
to predict locoregional relapses but only distant relapses.
More importantly, and unlike the 70-gene profiler developed
by the Amsterdam group [5,6], the NSABP recurrence
score does not have pure prognostic value but rather
predictive value regarding response to tamoxifen. A study
performed by the MD Anderson group [7] provides support
for this; in that study there was absence of correlation
between the score and rate of distant recurrence in 149
selected patients with node-negative breast cancer who did
not receive adjuvant systemic therapy. Notably, and despite
the difference between the two systems stated above, the
percentage of patients classified as low risk with the
NSABP score is similar to the one found with the 70-gene
profiler of the Amsterdam group, and is considerably higher
than the percentage of patients classed as low risk by
classical clinicopathological criteria.
Genome-wide studies have confirmed the existence of
clinically suspected subgroups of ER-positive breast
cancers with distinct outcomes and responses to therapy.
Aromatase inhibitors (AIs) are a newer class of endocrine
agents that have been found to be superior to tamoxifen in
the metastatic setting and recently also in the adjuvant
setting. These new agents are considerably more
expensive and are not without side effects, namely
osteoporosis and cardiovascular events. The role of
sequential administration of tamoxifen and an AI in
comparison with use of an AI alone remains to be
determined. A ‘biological identifier’ of tamoxifen resistance
could help to determine the patient population in which
alternative endocrine strategies and/or cytotoxic therapies
are clearly needed. The Oncotype™ multigene predictor
was able to identify a group of patients with a rate of
distant recurrence at 10 years of 30.5% – a risk similar to
that observed among node-positive breast cancer patients
– despite treatment with tamoxifen, which indicates a clear
need for more effective therapies in this group of patients.
More recently, the NSABP group has taken this work
further by analyzing the predictive potential of the
Oncotype™ predictor with respect to adjuvant chemo-
therapy [8]. In this clinical study, 2299 node-negative, ER-
positive breast cancer patients were randomly assigned to
receive tamoxifen alone or chemotherapy (either CMF
[cyclophosphamide, methotrexate and 5-fluorouracil] or MF
[methotrexate and 5-fluorouracil]) followed by tamoxifen.
Only 651 patients were evaluable for the recurrence score
substudy, mostly because of uncollected blocks.
Nevertheless, this subpopulation had similar characteristics
to the clinical population as a whole. Although there was
overall benefit from adding chemotherapy in these patients
(P = 0.02), when the Oncotype™ predictor was applied it
became apparent that this benefit was restricted to the
high risk patients (distant relapse-free survival 88% versus
60%;  P = 0.001); no benefit was seen in the low and
intermediate risk patients (distant relapse-free survival 90%
versus 89%; P = 0.71). The interaction test between gene
expression and chemotherapy was significant at 0.0368,
which indicates that the recurrence score could identify
those patients who clearly benefitted from the addition of
chemotherapy to adjuvant tamoxifen.
Despite its commercial availability in the USA, the
Oncotype™ multigene predictor should not yet be used in
clinical practice because it has not yet passed a crucial
phase of its validation – a well designed and adequately
powered prospective study. Such a trial is in advanced
stages of planning by the US Intergroup, and will
incorporate this new tool into treatment decision making in
node-negative, endocrine responsive patients. This trial is
along the same lines as the work of the European
TRANSBIG (an international translational research network
linked to the Breast International Group) consortium, which
is prospectively validating the 70-gene Amsterdam profiler
in the large multicentre MINDACT (Microarray in Node
Negative Disease May Avoid Chemotherapy) trial.
Only this type of international and multidisciplinary
collaboration will allow the incorporation of new techno-
logies and/or biological hypotheses into clinical trials,
facilitating their clinical implementation and transforming
the dream of individualized treatment into reality.
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